An interventional study of Exercise and Usual Care in MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, MASH - Metabolic Dysfunction-Associated Steatohepatitis and Liver Fibrosis/NASH, sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER). Recruiting at 1 site in Spain. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Consorcio Centro de Investigación Biomédica en Red (CIBER) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Fatty Liver with a site in Spain — 11 open to participants now, 12 under way, 4 of them phase 3. Fatty Liver · Spain.
Among the 28 studies in Fatty Liver with a site in Spain, this one is the 18th largest by planned enrollment of the 23 interventional ones that give a count, is one of 2 that started in 2026, is one of 12 with no phase, reaches primary completion later than 2 of the 11 other live ones, and was the 26th registered.
666 studies on the registry are indexed under Fatty Liver; 188 are open to participants now.
Browse Fatty Liver studies →11 of the 28 studies in Fatty Liver with a site in Spain are open now. Recruiting first, the newest first:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 20–80
Eli Lilly and Company · Sites in Spain, United States, Argentina and 31 more countries
Ages 18+
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 18–75
Boehringer Ingelheim · Sites in Spain, United States, Argentina and 34 more countries
Ages 18+
GlaxoSmithKline · Sites in Spain, United States, Argentina and 16 more countries
Ages 18–70
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 118 Fatty Liver studies recruiting now, 36 (31%) set no upper age limit and 63 (53%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 60 across 434 interventional studies indexed under Fatty Liver.
Median enrollment 165 across the 23 interventional studies, 450 across the 5 observational. Of the 13 that completed or were terminated, 3 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 28 have an industry lead sponsor. The 10 most frequent:
Consorcio Centro de Investigación Biomédica en Red (CIBER) is the lead sponsor of 18 studies on the registry; 6 are open to participants now.
Consorcio Centro de Investigación Biomédica en Red (CIBER) has 1 study filed under Fatty Liver — fewer than ten, so there is no comparison to draw.
3 of the studies in Fatty Liver with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07652892Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauImpact of Steatotic Liver Disease Associated With Metabolic Dysfunction (MASLD) on Frailty, Cognition, and Quality of Life. A Gender-sensitive Approach Towards a Comprehensive and Equitable Perspective. | 2027-02-25 |
| NCT07467512Consorcio Centro de Investigación Biomédica en Red (CIBER)Exercise for an Aging Liver (EXALIVER) | 2027-06 |
| NCT06613698GlaxoSmithKlineA Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease | 2027-11-26 |
Add all 3 to your calendar (.ics) → With an account.
Among the 28 studies in Fatty Liver with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn how physical exercise affects liver health in adults with metabolic dysfunction-associated steatotic liver disease (MASLD) or at-risk metabolic dysfunction-associated steatohepatitis (MASH); comparing responses between middle-aged adults (40-60 years old) and older adults (70 years and older) of any sex, as well as between participants with low-risk MASLD and high-risk MASH. The main question it aims to answer is:
Could an exercise program reduce liver fat, inflammation and fibrosis, regardless of age and disease severity?
Researchers will compare 4 different groups:
A) older adults with at risk MASH who will exercise B) middle-aged people with at risk MASH who will exercise C) middle-aged people with low-risk MASLD who will exercise D) middle-aged people with low-risk MASLD who will not exercise, receiving usual care.
Participants in the exercise groups will take part in a supervised 12-week exercise program that includes both strength and aerobic training, completed twice a week.
All participants, including those receiving usual care, will have health asssessments before and after the 12-week period to measure changes in liver health.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Older adults with Metabolic Dysfunction-Associated SteatoHepatitis aged 70 years or older who will complete the supervised 12-week exercise program.
Behavioral: Exercise
Middle-aged adults (40 to 60 years old) with at-risk metabolic dysfunction-associated SteatoHepatitis (MASH) who will complete a supervised 12-week exercise program
Behavioral: Exercise
Middle-aged adults (40 to 60 years old) with metabolic dysfunction-associated steatotic liver disease (MASLD) who will complete a supervised 12-week exercise program. This study arm will not recruit new participants. Instead, participants will be selected from a concluded clinical trial (NCT05897073; Study Arm: Experimental - Supervised Exercise Intervention), in which they completed the same exercise program and the same study outcome assessments of the present trial. These participants will be matched by sex, age and potential confounders to the individuals enrolled in the "Middle-aged adults with at-risk MASH who exercise" arm of the present study.
Behavioral: Exercise
Middle-aged adults (40 to 60 years old) with metabolic dysfunction-associated steatotic liver disease (MASLD) who receive usual care. This study arm will not recruit new participants. Instead, participants will be selected from a concluded clinical trial (NCT05897073, Study Arm: No Intervention: Usual-care control group), in which they received usual care and the same study outcome assessments of the present trial. These participants will be matched by sex, age and potential confounders to the individuals enrolled in the "Middle-aged adults with at-risk MASH who exercise" arm of the present study.
Behavioral: Usual Care
The exercise intervention will include 2 days/week of supervised moderate-high intensity resistance training (rating perceived exertion \>7, circuit-training, upper and lower body exercises involving major muscle groups) and high-intensity interval training (4 sets of 4-minute intervals at \>85% peak heat rate with 4-minute of active recovery at 50-65% peak heat rate, uphill treadmill walking). Moreover, participants will receive an individualized moderate-intensity goal-setting aerobic (walking) program to achieve a minimum of 135 minutes per week.
Participants will receive standard recommendations on healthy lifestyle based on Mediterranean dietary pattern and physical activity recommendations for weight loss and health promotion.
Change in hepatic fat content
Hepatic fat content will be determined by Proton Density Fat Fraction (PDFF) assessed by Magnetic Resonance Imaging (MRI)
Time frame: Change from baseline to 12 weeks
Change in liver inflammation and fibrosis
Iron-corrected T1 (cT1) will be determined though MRI to reflect liver tissue water content, correlating with histological features of fibroinflammation (ballooning, fibrosis, and NAS)
Time frame: Change from baseline to 12 weeks
Change in liver stiffness
Determined by vibration-controlled Transient Elastography (Fibroscan ®, VCTE). This is an ultrasound-based technique widely used in clinical practice to diagnose and monitor fibrosis progression. Liver stifness measurement increases with liver fibrosis.
Time frame: Change from baseline to 12 weeks.
Change in Enhanced Liver Fibrosis (ELF) Score
Fasting blood samples will be used to assess the Enhanced Liver Fibrosis (ELF) serum biomarker. The ELF score reflects the risk of advanced liver fibrosis, with higher values indicating higher risk.
Time frame: Change from baseline to 12 weeks
Change in Pro-C3 serum levels
Fasting blood samples will be used to asses Pro-C3 serum levels, a biomarker of liver fibrosis. Higher PRO-C3 levels indicate ongoing fibrotic activity
Time frame: Change from baseline to 12 weeks
Change in NIS4 serum biomarker of liver fibrosis
Fasting blood samples will be used to asses NIS4, a blood-based diagnostic tool designed to identify patients with at-risk MASH. It generates a composite score stratifying patients by risk.
Time frame: Change from baseline to 12 weeks
Change in Metabolomics Advanced Steatohepatitis Fibrosis Score (MASEF)
Fasting blood samples will be used to asses Metabolomics Advanced Steatohepatitis Fibrosis Score (MASEF) in serum samples. Is a proprietary algorithm that generates a numeric score that reflects the likelihood of a patient having at-risk MASH.
Time frame: Change from baseline to 12 weeks
Change in visceral adipose tissue
Visceral adipose tissue will be assessed by Magnetic Resonance Imaging (MRI)
Time frame: Change from baseline to 12 weeks
Change in pancreatic fat content
Pancreatic fat content will be assessed by Magnetic Resonance Imaging (MRI)
Time frame: Change from baseline to 12 weeks
Change in abdominal subcutaneous adipose tissue
Abdominal subcutaneous adipose tissue will be assessed by Magnetic Resonance Imaging (MRI)
Time frame: Change from baseline to 12 weeks
Change in abdominal intermuscular fat content
Abdominal intermuscular fat content will be assessed by Magnetic Resonance Imaging (MRI)
Time frame: Change from baseline to 12 weeks
Change in abdominal intramuscular fat content
Abdominal intramuscular fat content will be assessed by Magnetic Resonance Imaging (MRI)
Time frame: Change from baseline to 12 weeks
Change in abdominal skeletal muscle tissue
Abdominal skeletal muscle tissue will be assessed by Magnetic Resonance Imaging (MRI)
Time frame: Change from baseline to 12 weeks
Change in values of fasting glucose
Fasting blood samples will be used to assess glucose
Time frame: Change from baseline to 12 weeks
Change in values of HbA1c
Fasting blood samples will be used to assess HbA1c. Higher fasting HbA1C values indicates poorer glucemic control.
Time frame: Change from baseline to 12 weeks
Change in values of fasting insulin
Fasting blood samples will be used to assess insulin
Time frame: Change from baseline to 12 weeks
Change in levels of mean glucose (Continuous Glucose Monitoring)
24-hour, diurnal and nocturnal mean glucose over 14 days will be assessed by Continuous Glucose Monitoring during 2 weeks
Time frame: Change from baseline to 12 weeks.
Change in fasting lipid profile
Fasting blood samples will be used to assess levels of triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol an total cholesterol.
Time frame: Change from baseline to 12 weeks
Change in alkaline phosphatase
Fasting blood samples will be used to assess serum alkaline phosphatase using standard clinical chemistry methods.
Time frame: Baseline to 12 weeks
Change in alanine aminotransferase (ALT)
Fasting blood samples will be used to assess serum alanine aminotransferase (ALT) using standard clinical chemistry methods.
Time frame: Baseline to 12 weeks
Change in gamma-glutamyl transferase (GGT)
Fasting blood samples will be used to assess serum gamma-glutamyl transferase (GGT) using standard clinical chemistry methods.
Time frame: Baseline to 12 weeks
Change in total bilirubin
Fasting blood samples will be used to assess total serum bilirubin using standard clinical chemistry methods.
Time frame: Baseline to 12 weeks
Change in creatinine
Fasting blood samples will be used to assess serum creatinine using standard clinical chemistry methods.
Time frame: Baseline to 12 weeks
Change in estimated glomerular filtration rate (eGFR)
eGFR will be calculated from serum creatinine using a standard equation (e.g., CKD-EPI 2021), as implemented by the study laboratory.
Time frame: Baseline to 12 weeks
Change in values of C-reactive protein
Fasting blood samples will be used to assess levels of C-reactive protein. Higher values indicate inflammation in the body.
Time frame: Change from baseline to 12 weeks
Change in values of interleukin 6
Fasting blood samples will be used to assess levels of interleukin 6. Higher basal levels often indicating greater inflammation or metabolic stress.
Time frame: Change from baseline to 12 weeks]
Change in blood pressure
Systolic and Diastolic blood pressure will be assessed by blood pressure monitor
Time frame: Change from baseline to 12 weeks
Change in waist, hip and neck circumference
Circumference will be assessed by measuring tape following the procedures outlined by the International Society for the Advancement of Kinanthropometry
Time frame: Change from baseline to 12 weeks.
Change in body weight
Body weight will be measured by a digital scale
Time frame: Change from baseline to 12 weeks
Change in moderate-to-vigorous physical activity (MVPA)
Moderate-to-vigorous physical activity (minutes per day) will be estimated from wrist-worn accelerometry recorded over a 2-week monitoring period.
Time frame: Baseline to 12 weeks
Change in light physical activity
Light physical activity (minutes per day) will be estimated from wrist-worn accelerometry recorded over a 2-week monitoring period.
Time frame: Baseline to 12 weeks
Change in sedentary time
Sedentary time (minutes per day) will be estimated from wrist-worn accelerometry recorded over a 2-week monitoring period.
Time frame: Baseline to 12 weeks
Change in total activity counts
Total activity counts per day will be estimated from wrist-worn accelerometry recorded over a 2-week monitoring period.
Time frame: Baseline to 12 weeks
Change in Subjective sleep quality
Subjective sleep quality will be assessed by the Pittsburgh Sleep Quality Index (PSQI). Minimum value is 0 (never) and maximum value is 3 (3 or more times per week). Higher values mean a worse outcome.
Time frame: Baseline to 12 weeks
Change in total sleep time
Total sleep time (minutes per night) will be estimated from wrist-worn accelerometry recorded over a 2-week monitoring period.
Time frame: Baseline to 12 weeks
Change in Cardiorespiratory Fitness
Cardiorespiratory fitness measured by maximum treadmill test
Time frame: Change from baseline to 12 weeks
Change in Lower-body muscular performance
Lower body muscular performance measured by chair stand test.
Time frame: Change from baseline to 12 weeks
Change in Upper muscular strength
Upper body muscular strength measured by hand grip strength test.
Time frame: Change from baseline to 12 weeks
Change in Quality of life
Quality of life will be assessed by the Rand Short Form 36 (SF-36). This questionnaire provides an score ranged from 0 to 100. Higher values mean better quality of life.
Time frame: Changes from baseline to 12-weeks
Change EuroQol Visual Analogue Scale (EQ-VAS) score
The EQ-VAS is a vertical 0-100 scale used in the EuroQol EQ-5D instrument to measure a patient's self-rated, current overall health. It ranges from 0 (worst imaginable health) to 100 (best imaginable health), allowing patients to quantify their perceived health status.
Time frame: Changes from baseline to 12-weeks
Change in mid-thigh subcutaneous adipose tissue area
Mid-thigh subcutaneous adipose tissue area will be quantified from segmented magnetic resonance imaging (MRI) slices.
Time frame: Baseline to 12 weeks
Change in mid-thigh intramuscular fat content
Mid-thigh intramuscular fat content will be quantified from segmented magnetic resonance imaging (MRI) slices.
Time frame: Baseline to 12 weeks
Change in mid-thigh intermuscular fat content
Mid-thigh intermuscular fat content will be quantified from segmented magnetic resonance imaging (MRI) slices.
Time frame: Baseline to 12 weeks
Change in mid-thigh skeletal muscle cross-sectional area
Mid-thigh skeletal muscle cross-sectional area will be quantified from segmented magnetic resonance imaging (MRI) slices.
Time frame: Baseline to 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Jun 2027, 15 months after the start.
Of 136 non-industry interventional studies with no phase under Fatty Liver, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 15 months is below that.
Counting every sponsor, half of 145 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Consorcio Centro de Investigación Biomédica en Red (CIBER)